Cannabics Pharmaceuticals Inc (OTCMKTS: CNBX) continues to rise in recent weeks as pot stocks heat up across the board since dropping to as low as $0.271. The stock popped to highs well over $1.30 back in September but collapsed along with the rest of pot stocks after Canada legalized cannabis in October.
On January 8 CNBX announced U.S.-based partner and investor Cannabics Pharmaceuticals Inc., a leader in personalized cannabinoid medicine focused on cancer and its side effects, is converting its $1 million convertible loan to Seedo into common shares of the company. This signals increasing support from Cannabics who announced in August 2018 details of its investment in Seedo along with news of the companies’ partnership to develop the world’s first controlled device for growing medical cannabis at home. The collaboration between these industry leaders is poised to provide patients with the precision growth technology necessary to ensure standardized control over their medical cannabis supply. Seedo is a market leading high-tech company providing the cannabis and agriculture industries with the world’s first fully automated and controlled indoor growing machine.
Cannabics Pharmaceuticals Inc bills itself as a U.S public company that has developed a platform which leverages novel drug-screening tools and artificial intelligence to develop cannabinoid-based therapies for cancer that are more precise to a patient’s genetic profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer. Cannabics is focusing on natural cannabinoids and its R&D open its doors for collaboration in the discovery of new anticancer compounds.
Last year Cannabics opened a genetics lab. This Tel Aviv cannabis research laboratory will focus on developing diagnostic tools based on the human genome, tumor genetics, and cannabinoids. Cannabics has been immersed in pharmaceutical R&D through their subsidiary Grin Ultra, a licensed Israeli company since 2014. Since that year the Israeli Ministry of Health has granted them the go-ahead for cannabinoid based research. Their research is based on developing cannabinoid medicine specifically for cancer patients. Currently, they administer cannabis in pill form to cancer patients as a treatment for their lack of appetite in one ongoing clinical study. In the wings are two more studies mean to help ease the devastating symptoms of cancer treatment.
Both the company and their Laboratory are broadly licensed by the Ministry of Health in Israel specifically for R&D on Cannabis. We see great potential in scientific collaborations with like-minded companies that are engaged in cannabinoid medicines and diagnostics. Currently, we are in the final stages of finalizing our agreement with a company engaged in ophthalmic disorders to develop a product to compete with Steroids in the ocular disease market.
To Find out the inside Scoop on CNBX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Cannabics is rapidly expanding its database of cancer and cannabinoids and established a library of cannabinoid compounds to explore the biological versatility and entourage effect. Recently the company has been granted a patent in Israel on its core technology of screening the effectiveness of cannabis compounds on human biopsies. The research and development center, in Israel, has leveraged its capabilities and accomplished the implementation of the patented technology.
Cannabics filed two new provisional patent applications with the US Patent office in recent months; in November they filed a patennt applicaiton for its novel delivery system designed specifically for personalized targeted cannabinoid-based therapy. The title of the filing is “A System and Method for Providing Magnetic targeting of Cannabinoids to Cancer Patients”. This cutting-edge technology fuses specific cannabinoids to iron particles through molecular bonding, which can then be targeted to a specific physical location in the patient’s body.This innovative non-invasive approach allows internal systemic delivery of cannabinoids to the actual area of live tumors within the patient. This is one of several recent patents which has made Cannabics Pharmaceuticals one of the world’s leaders in the emerging field of targeted personalized medicine. In December Cannabics filed a patent applicaiton for its technology that will enable the transfer of data from its proprietary personalization platform of cannabis strains and cancer to medical cannabis businesses worldwide and overcome the limitations of exporting and importing cannabinoid compounds due to regulation.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $52 million market valuation CNBX has $1.4 million in the treasury, very little debt and tiny revenues so far. CNBX is an exciting story developing in small caps; focused on being the leader in personalized cannabinoid medicine focused on cancer and its side effects, with a team of scientists diligently working to develop and expand their intellectual property portfolio. CNBX stock has a long history of big moves and has been largely ignored in recent months as the rest of the cannabis sector has been booming! Investors in CNBX are betting this is about to change. We will be updating on CNBX when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CNBX.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in CNBX either long or short and we have not been compensated for this article.